Climb Bio initiates trials, strengthens leadership, and extends cash runway.

Climb Bio has initiated Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) and Phase 1 trial of subcutaneous formulation. Clinical trials in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) are ongoing with initial data expected in H2 2026. The company has strengthened its leadership team and expects a cash runway through 2027.